Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Other Non Operating Income came in at $273000.0 in Q2 2026, down 96.92% YoY from $8.9 million in Q2 2025, and up 106.36% on a QoQ basis from -$4.3 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Other Non Operating Income data on file, last reported at $273000.0 in Q2 2026.
- Quarterly Other Non Operating Income fell 96.92% year-over-year to $273000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$81.5 million (up 11.69% YoY) and the FY2025 annual result came in at $5.2 million, up 102.88% from the prior year.
- Other Non Operating Income improved to $273000.0 in Q2 2026, from -$4.3 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $9.2 million in Q1 2025 to a low of -$80.8 million in Q4 2024.
- A 5-year average of -$30.1 million and a median of -$24.9 million in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income plunged 691.56% — and 2025, when it surged 163.19%.
- Tracing ALNY's Other Non Operating Income over 5 years: stood at -$2.6 million in 2022, then sank by 691.56% to -$20.4 million in 2023, then plunged by 297.26% to -$80.8 million in 2024, then surged by 95.84% to -$3.4 million in 2025, then soared by 108.12% to $273000.0 in 2026.
- The last three Other Non Operating Income figures came in at $273000.0 (Q2 2026), -$4.3 million (Q1 2026), and -$3.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 273,000.00 |
| Mar 31, 2026 | -89,000.00 |
| Dec 31, 2025 | -3.36 Mn |
| Sep 30, 2025 | -74.15 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Mar 31, 2025 | -55,000.00 |
| Dec 31, 2024 | -180.53 Mn |
| Sep 30, 2024 | -29.53 Mn |
| Jun 30, 2024 | -55.71 Mn |
| Mar 31, 2024 | -33,000.00 |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 10,000.00 |
| Jun 30, 2023 | -35.42 Mn |
| Mar 31, 2023 | 5,000.00 |
| Dec 31, 2022 | -1.62 Mn |
| Sep 30, 2022 | -76.60 Mn |
| Jun 30, 2022 | -34,000.00 |
| Mar 31, 2022 | -35,000.00 |
| Sep 30, 2021 | 17.72 Mn |
| Jun 30, 2021 | -58,000.00 |